Discovery Stage IND EXEMPT SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Explore the relationship between drug target topoisomerase II gene single nucleotide
polymorphisms and Etoposide (VP-16) therapeutic-effects in patients with small cell lung
cancer, based on Oxford precisely sequencing drug targets' genes.
Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms
and Etoposide (VP-16) side-effects in patients with small cell lung cancer, based on Oxford
precisely sequencing drug targets' genes.
Phase:
Phase 3
Details
Lead Sponsor:
Dr. Han Xu, President/CEO / PD / PI / Monitor / IRB Chair Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair